Delayed haemolytic and serologic transfusion reactions: Pathophysiology, treatment and prevention

Current Opinion in Hematology

Volumn 25, Issue 6, 2018, Pages 459-467

  Siddon, Alexa J ^a,b,c   Kenney, Barton C ^c   Hendrickson, Jeanne E ^a   Tormey, Christopher A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Department of Pathology ^*  (United States)

Author keywords

anamnestic responses; antibody evanescence; bystander haemolysis; delayed haemolytic transfusion reactions; delayed serologic transfusion reactions; hyperhaemolysis; hyperhaemolytic delayed transfusion reactions

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

BLOOD TRANSFUSION; HEMOLYSIS; HUMAN; PATHOPHYSIOLOGY; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; HEMOLYSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 85054345115     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000462     Document Type: Review

References (65)

1. Zimring JC, Spitalnik SL,. Pathobiology of transfusion reactions. Annu Rev Pathol Mech Dis 2015; 10: 83-110.
2. Pineda AA, Vamvakas EC, Gorden LD,. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion 1999; 39: 1097-1103.
3. Kleinman S, Chain P, Robillard P,. Risks associated with transfusion of cellular components in Canada. Trans Med Rev 2003; 17: 120-162.
4. US Food and Drug Administration. Transfusion/donation fatalities. Rockville, MD: 2018; https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/default.htm [cited 9 April 2018].
5. UK Serious Hazards of Transfusion Organization. Annual reports & summaries. Manchester, UK: 2016; https://www.shotuk.org/shot-reports/. [cited 9 April 2018].
6. Chou ST, Jackson T, Vege S,. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122: 1062-1071.
7. Maluskova A, Mrazek F, Pauliskova M,. Association of HLA-DRB1 and HLA-DQB1 with red-blood-cell alloimmunization in the Czech population. Vox Sang 2017; 112: 156-162.
8. Fasano RM, Booth GS, Miles M,. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015; 168: 291-300.
9. Ryder AB, Hendrickson JE, Tormey CA,. Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. Br J Haematol 2016; 174: 483-485.
10. Celli R, Schulz W, Hendrickson JE,. A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sang 2017; 112: 469-472.
11. Zheng Y, Pollak J, Henderson K,. A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic telangiectasia. Transfusion 2018; 58: 775-780.
12. Calabro S, Gallman A, Gowthaman U,. Bridging channel dendritic cells induce immunity to transfused red blood cells. J Exp Med 2016; 213: 887-896.
13. Gibb DR, Liu J, Santhanakrishnan M,. B cells require Type 1 interferon to produce alloantibodies to transfused KEL-expressing red blood cells in mice. Transfusion 2017; 57: 2595-2608.
14. Patel SR, Bennett A, Girard-Pierce K,. Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice. Blood Adv 2018; 2: 105-115.
15. Hendrickson JE, Eisenbarth SC, Tormey CA,. Red blood cell alloimmunization: new findings at the bench and new recommendations for the bedside. Curr Opin Hematol 2016; 23: 543-549.
16. Hendrickson JE, Tormey CA,. Understanding red blood cell alloimmunization triggers. Hematology Am Soc Hematol Educ Program 2016; 2016: 446-451.
17. Ramsey G, Larson P,. Loss of red cell alloantibodies over time. Transfusion 1988; 28: 162-165.
18. Ramsey G, Smietana SJ,. Long-term follow-up testing of red cell alloantibodies. Transfusion 1994; 34: 122-124.
19. Schonewille H, Haak HL, van Zijl AM,. RBC antibody persistence. Transfusion 2000; 40: 1127-1131.
20. Reverberi R,. The persistence of red cell alloantibodies. Blood Transfus 2008; 6: 225-234.
21. Tormey CA, Stack G,. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009; 49: 505-512.
22. Rosse WF, Gallagher D, Kinney TR,. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76: 1431-1437.
23. Williams LA 3rd, Lorenz RG, Tahir A,. High percentage of evanescent red cell antibodies in patients with sickle cell disease highlights need for a national antibody database. South Med J 2016; 109: 588-591. This manuscript reinforces the notion that high evanescence rates can be observed in sickle cell populations and argues for the establishment of a regional or national alloantibody database to combat the problem.
24. Nadarajan VS,. The prevalence, immunogenicity, and evanescence of alloantibodies to MUT and Mur antigens of GP.Mur red blood cells in a Southeast Asian patient cohort. Transfusion 2018; 58: 1189-1198. This study sheds light on the relatively little studied MUT and Mur antigens, providing insight into the high evanescence rates associated with antibodies to these antigens, as well as providing details on the immunogenicity of these little examined antigens.
25. Winters JL, Richa EM, Bryant SC,. Polyethylene glycol antiglobulin tube versus gel microcolumn: influence on the incidence of delayed hemolytic transfusion reactions and delayed serologic transfusion reactions. Transfusion 2010; 50: 1444-1452.
26. athat are detected by solid-phase red blood cell adherence but missed by gel testing can cause hemolytic transfusion reactions. Transfusion 2016; 56: 2973-2979.
27. Stack G, Tormey CA,. Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence. Transfusion 2016; 56: 2662-2667. The results of this study indicate that routine antibody screening, performed in a random, nonsystematic way, can miss nearly two-thirds of new alloimmunization rates, significantly increasing risks for DHTRs.
28. Meinderts SM, Sins JWR, Fijnvandraat K,. Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease. Blood 2017; 130: 2121-2130. This study is amongst the first to examine Fc gamma receptor polymorphisms and their impact on alloimmunization. As part of the study, the authors also investigated whether such polymorphisms had an impact on the occurrence of delayed haemolytic reactions.
29. Tormey CA, Stack G,. The characterization and classification of concurrent blood group antibodies. Transfusion 2009; 49: 2709-2718.
30. Noiret L, Slater A, Higgins JM,. Determinants of red blood cell alloantibody detection duration: analysis of multiply alloimmunized patients supports peritransfusion factors. Transfusion 2017; 57: 1930-1937.
31. Hendrickson JE, Tormey CA,. McManus LM, Mitchell RN,. The RBC as a target of damage. Pathobiology of human disease. San Diego, CA: Elsevier; 2014. 3068-3080.
32. Jang JE, Hod EA, Spitalnik SL,. CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions. J Clin Invest 2011; 121: 1397-1401.
33. Tormey CA, Stack G,. Estimation of combat-related blood group alloimmunization and delayed serologic transfusion reactions in U.S. military veterans. Mil Med 2009; 174: 503-507.
34. Centers for Disease Control. National Healthcare Safety Network biovigilance module surveillance protocol. Atlanta, GA: 2018; https://www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf [cited 9 April 2018].
35. Torres R, Kenney B, Tormey CA,. Diagnosis, treatment, and reporting of adverse effects of transfusion. Lab Med 2012; 43: 217-231.
36. Talano JA, Hillery CA, Gottschall JL,. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003; 111: e661-e665.
37. Gupta S, Fenves A, Nance ST,. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Transfusion 2015; 55: 623-628.
38. Habibi A, Mekontso-Dessap A, Guillaud C,. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol 2016; 91: 989-994. One of the most extensive studies performed to date regarding delayed hyperhaemolytic reactions in sickle cell disease, providing unique insights into the pathophysiology, treatment and outcomes of these rare, but deadly reactions.
39. Karafin MS, Singavi A, Johnson ST,. A fatal case of immune hyperhemolysis with bone marrow necrosis in a patient with sickle cell disease. Hematol Rep 2017; 9: 6934.
40. Mekontso Dessap A, Pirenne F, Razazi K,. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol 2016; 91: 1181-1184. The efforts of these investigators resulted in a unique and helpful scoring system to better identify delayed haemolytic reactions in patients with sickle cell disease.
41. bcausing an acute hemolytic transfusion reaction. Vox Sang 1994; 66: 206-209.
42. Strupp A, Cash K, Uehlinger J,. Difficulties in identifying antibodies in the Dombrock blood group system in multiply alloimmunized patients. Transfusion 1998; 38: 1022-1025.
43. aantigens, not detected by cross-matching. Transfusion 2006; 46: 244-249.
44. Chadebech P, Habibi A, Nzouakou R,. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion 2009; 49: 1785-1792.
45. Mendoza R, Moor M, Passwater M,. Delayed hemolytic transfusion reaction without detectable autoantibodies or alloantibodies: a possible role of phosphatidylserine exposure on donor RBCs. Lab Med 2011; 42: 653-656.
46. Win N, Lee E, Needs M,. Measurement of macrophage marker in hyperhaemolytic transfusion reaction: a case report. Transfus Med 2012; 22: 137-141.
47. Mwesigwa S, Moulds JM, Chen A,. Whole-exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition. Transfusion 2018; 58: 726-735.
48. AABB. Annual meeting program. Bethesda, MD; 2018. http://www.aabb.org/annual-meeting/schedule/Pages/session-details.aspx?PC=9321_TC&MC=AABB16&IsSam=0 [cited 9 April 2018].
49. Mazzei CA, Popovsky MA, Kopko PM,. Fung MK, Grossman BJ, Hillyer CD,. Noninfectious complications of blood transfusion. Technical manual 18th ed. Bethesda, MD: AABB Press; 2014. 665-696.
50. Tormey CA, Stack G,. Limiting the extent of a delayed hemolytic transfusion reaction with automated red blood cell exchange. Arch Pathol Lab Med 2013; 137: 861-864.
51. Irani MS, Karafin MS, Ernster L,. Red cell exchange to mitigate a delayed hemolytic transfusion reaction in a patient transfused with incompatible red blood cells. J Clin Apher 2017; 32: 59-61.
52. Namikawa A, Shibuya Y, Ouchi H,. A case of ABO-incompatible blood transfusion treated by plasma exchange therapy and continuous hemodiafiltration. CEN Case Rep 2018; 7: 114-120.
53. Uhlmann EJ, Shenoy S, Goodnough LT,. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion 2014; 54: 384-388.
54. Gardner K, Hoppe C, Mijovic A,. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol 2015; 170: 745-756.
55. Danaee A, Inusa B, Howard J,. Hyperhemolysis in patients with hemoglobinopathies: a single-center experience and review of the literature. Trans Med Rev 2015; 29: 220-230.
56. Cattoni A, Cazzaniga G, Perseghin P,. An attempt to induce transient immunosuppression preerythrocytapheresis in a girl with sickle cell disease, a history of severe delayed hemolytic transfusion reactions and need for hip prosthesis. Hematol Rep 2013; 5: 36-38.
57. Noizat-Pirenne F, Habibi A, Mekontso-Dessap A,. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sang 2015; 108: 262-267.
58. Boonyasampant M, Weitz IC, Kay B,. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion 2015; 55: 2398-2403.
59. Dumas G, Habibi A, Onimus T,. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 2016; 127: 1062-1064.
60. Hendrickson JE, Tormey CA, Shaz BH,. Red blood cell alloimmunization mitigation strategies. Transfus Med Rev 2014; 28: 137-144.
61. Sloan SR,. The importance of antibody screens after transfusions. Transfusion 2016; 56: 2653-2654.
62. Unni N, Peddinghaus M, Tormey CA,. Record fragmentation due to transfusion at multiple healthcare facilities: a risk factor for delayed hemolytic transfusion reactions. Transfusion 2014; 54: 98-103.
63. Harm SK, Yazer MH, Monis GF,. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 2014; 141: 256-261.
64. Castro O, Oneal P, Medina A,. Preventing delayed hemolytic transfusion reactions in sickle cell disease. Transfusion 2016; 56: 2899-2900.
65. Schwickerath V, Kowalski M, Menitove JE,. Regional registry of patient alloantibodies: first-year experience. Transfusion 2010; 50: 1465-1470.